Ocular Therapeutix (OCUL) CEO Pravin Dugel Sells Shares, Gifts Stock

What Happened

• Pravin Dugel, Executive Chairman, President and CEO of Ocular Therapeutix (OCUL), had 21,649 shares sold on August 24, 2026 at a weighted average price of $10.77 per share for proceeds of about $233,160. The sale was executed under an automatic sell-to-cover instruction to satisfy tax withholding related to restricted stock units that vested on August 22, 2026.
• On August 25, 2026, 50,092 shares were transferred by the reporting person’s spouse into the "Pravin Dugel 2024 Irrevocable Trust" for no consideration; Dugel is trustee and the sole lifetime beneficiary and thus remains the beneficial owner of those shares.

Key Details

• Transactions: 2026-08-24 sale — 21,649 shares @ weighted avg $10.77 = ~$233,160; 2026-08-25 gift/transfer — 50,092 shares moved to trust (no cash).
• Price range: sales occurred at prices between $10.64 and $10.90 (weighted average reported). The filer will provide a breakdown on request.
• Reason for sale: sell-to-cover tax withholding tied to RSU vesting (automatic instruction adopted Feb 21, 2024); sale was not a discretionary trade.
• Beneficial ownership: the reporting person remains the beneficial owner of the trust-held shares (he is trustee and sole lifetime beneficiary). The filing does not state an aggregate post-transaction share total.
• Filing: Form 4 filed Aug 26, 2026 reporting transactions from Aug 24–25, 2026.

Context

• The 21,649-share sale appears administrative (tax withholding on vested RSUs), not a discretionary divestiture — such sell-to-cover transactions are routine and do not necessarily signal a change in insider conviction.
• The 50,092-share transfer to an irrevocable trust was a gift by the spouse; gifts and intra-family trust transfers generally do not indicate market sentiment since Dugel retains beneficial ownership.